Wird geladen...
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
Metastatic pancreatic adenocarcinoma remains one of the deadliest cancer diagnoses with 5-year survival rates as low as 3%. For decades, gemcitabine remained the mainstay of systemic therapy before the approvals of FOLFIRINOX and gemcitabine with nab-paclitaxel. Despite these advances in the early 2...
Gespeichert in:
| Veröffentlicht in: | Ann Pancreat Cancer |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7720884/ https://ncbi.nlm.nih.gov/pubmed/33294843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc-2020-pda-05 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|